Photo
Business Update

Reuters business newsletter, your daily business coverage.

Subscribe

Patent office head sees law clearing Congress

Tue Feb 5, 2008 7:20pm EST

Reporter's Notebook

[-] Text [+]

WASHINGTON (Reuters) - Patent legislation that has been a political battleground for years will probably pass Congress this year, John Dudas, director of the U.S. Patent and Trademark Office, said on Tuesday.

The U.S. House of Representatives passed a patent overhaul bill on September 7 but it stalled in the Senate because of opposition from drug firms like Eli Lilly & Co (LLY.N: Quote, Profile, Research, Stock Buzz), seed and herbicide company Monsanto Co (MON.N: Quote, Profile, Research, Stock Buzz) and smaller tech companies who said the proposed changes would leave them vulnerable.

But Dudas, a former congressional staffer who has been meeting stakeholders in the bill, told the Reuters Regulation Summit he expected the two sides to reach agreement.

"I'm optimistic that we'll have patent reform because what we see is that there are very real answers," said Dudas.

Under current law, damages can be calculated as the entire market value of the product. That number can be tripled when the patent infringement is found to be intentional or willful.

The Senate bill, which may well change before it goes to the floor, would allow damages to be based on what the infringer would have had to pay if he had bought a license for the patent, according to a draft report that summarizes major portions of the bill.

Other controversial proposals involve limiting how court venues can be chosen, allowing post-grant reviews of patents and changing the punishment for "inequitable conduct." Inequitable conduct refers to a failure to inform the patent office of information relevant to patentability. This can lead to invalidation of a patent.

Tom DiLenge, general counsel for the Biotechnology Industry Organization, has called how to calculate damages for infringement "the toughest nut to crack."

Both the Bush administration and the pharmaceutical industry staunchly oppose the damages portion of the House version of the bill.  Continued...

 
Global Environment Oct 06 - 8, 2008 Energy
Autos II Sep 30 - Oct 01, 2008 Hotels/Casinos
Restructuring Sep 22 - 26, 2008 Financial Services/Exchanges
Autos Sep 15 - 17, 2008 Autos
Russia Investment Sep 08 - 9, 2008 Country Summits

What are Summits?

Reuters Summits are your direct link to top business leaders, investors and regulators. Our journalists interview heavyweights in a particular industry, spin out hard-hitting breaking news and sharp analysis that can often move markets. If you want to understand what the insiders are thinking, look for Reuters Summits.  Launch Full Video 

 

Stay connected. Get e-mailed alerts with schedules, speaker lists, and headlines from upcoming and live Industry Summits.